Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 447  

    Article Cited by others

ORIGINAL ARTICLE

177Lu-DOTATATE peptide receptor radionuclide therapy in patients with borderline low and discordant renal parameters: Treatment feasibility assessment by sequential estimation of triple parameters and filtration fraction

Naik Chinna, Basu Sandip

Year : 2018| Volume: 17| Issue : 1 | Page no: 12-20

   This article has been cited by
 
1 Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy
Daphne M. V. Huizing,Else A. Aalbersberg,Michelle W. J. Versleijen,Margot E. T. Tesselaar,Iris Walraven,Max J. Lahaye,Berlinda J. de Wit–van der Veen,Marcel P. M. Stokkel
Cancer Imaging. 2020; 20(1)
[Pubmed]  [Google Scholar] [DOI]
2 Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors
Sandip Basu,Rahul V. Parghane,Rahul V. Kamaldeep,Sudipta Chakraborty
Seminars in Nuclear Medicine. 2020;
[Pubmed]  [Google Scholar] [DOI]
3 Peptide Receptor Radionuclide Therapy in the Management of Neuroendocrine Tumors (Neoplasms): Fundamentals and Salient Clinical Practice Points for Medical Oncologists
Sandip Basu,Rahul Parghane,Rohit Ranade,Pradeep Thapa,Anant Ramaswamy,Vikas Ostwal,Bhawna Sirohi,Dipanjan Panda,Shailesh V Shrikhande
Indian Journal of Medical and Paediatric Oncology. 2019; 40(02): 165
[Pubmed]  [Google Scholar] [DOI]

 

Read this article